Hua Hong Semiconductor (688347) share price in focus before Shanghai open as Feb 10-12 votes loom
2 February 2026
1 min read

Hua Hong Semiconductor (688347) share price in focus before Shanghai open as Feb 10-12 votes loom

Shanghai, Feb 2, 2026, 08:31 (GMT+8) — Premarket

Hua Hong Semiconductor’s Class A shares, listed in Shanghai, are poised to resume trading Monday. They closed the previous session at 155.10 yuan, marking a 0.38% increase. 1

This week is key as investors focus on two dates: a shareholder vote on a share-issuance plan and the board’s review of fourth-quarter results. Either event could reshape the near-term outlook for a stock that’s been influenced as much by event risk as by demand chatter.

Hong Kong Exchanges and Clearing Limited announced its board will convene on Feb. 12 at 10:00 a.m. to review and approve unaudited Q4 results for the period ending Dec. 31. The notice was signed by chairman and president Peng Bai.

The company also announced in a separate filing that it will release its fourth-quarter results after the close on Feb. 12, followed by an investor briefing from 5:00 p.m. to 6:00 p.m. via web and phone.

Shareholders will gather on Feb. 10 to vote on a plan to issue renminbi-denominated shares aimed at acquiring “target assets” and raising supporting funds, along with other proposals. The agenda features a “whitewash waiver,” a Hong Kong takeovers-rule provision that can exempt a mandatory offer obligation if control shifts via a share issuance.

Foundry shares worldwide have slipped amid concerns about capacity and supply chain issues. Nvidia CEO Jensen Huang emphasized his high wafer demand this year, urging Taiwan Semiconductor Manufacturing Co to ramp up production. This highlights ongoing tightness in parts of the supply chain. 2

Investors eye Hua Hong’s results mainly for updates on utilisation rates, pricing, and product mix, plus any hints on funding requirements linked to upcoming deals. Reuters describes the company as providing wafer foundry services in specialty areas like power devices, analog and power management, and RF. 3

Risks remain evident. The Feb. 10 resolutions and the broader deal still need approvals and must meet conditions, so any hold-up could shift key deadlines. On earnings, the downside is straightforward: weaker demand or margin numbers might quickly sour sentiment, especially if rivals like Semiconductor Manufacturing International Corp follow a different path.

Key catalysts are coming up fast. Monday’s open will set the tone after the weekend, with eyes quickly shifting to the shareholder meeting on Feb. 10 and the board meeting on Feb. 12, which includes a results release after the close and an investor briefing.

Stock Market Today

MARA stock jumps 22% into weekend as bitcoin whipsaws; Monday risk test looms

MARA stock jumps 22% into weekend as bitcoin whipsaws; Monday risk test looms

7 February 2026
MARA shares jumped 22.4% to $8.24 Friday, trading higher after hours, as the company moved $87 million in bitcoin to major custodians. About 82.4 million MARA shares changed hands. Bitcoin hovered near $68,928 Saturday. A MARA filing showed its general counsel had shares withheld for taxes on vested stock units, not an open market sale.
Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

7 February 2026
Apple shares closed up 0.8% at $278.12 Friday, then slipped 0.3% after hours. A global DRAM shortage is raising component costs, putting pressure on Apple’s pricing ahead of its Feb. 24 shareholder meeting. CEO Tim Cook said memory prices will rise “sharply” but gave no details on possible iPhone price hikes. Investors await signals before next week’s U.S. inflation data.
Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

7 February 2026
Roivant shares surged 22.4% to $25.82 after Phase 2 data showed its drug brepocitinib outperformed placebo in cutaneous sarcoidosis, with no serious adverse events. The company plans a Phase 3 trial in 2026 and has filed for FDA approval in dermatomyositis. Quarterly revenue reached $2 million, with a $313.7 million loss. Cash holdings stood at $4.5 billion.
Suzhou TFC Optical Communication stock price: 300394.SZ watched after 11% jump as silicon photonics trade heats up
Previous Story

Suzhou TFC Optical Communication stock price: 300394.SZ watched after 11% jump as silicon photonics trade heats up

ASE Technology stock drops 4% ahead of results — what to watch for 3711.TW and NYSE:ASX
Next Story

ASE Technology stock drops 4% ahead of results — what to watch for 3711.TW and NYSE:ASX

Go toTop